Literature DB >> 24123111

Diagnostic accuracy of (18) F-methylcholine positron emission tomography/computed tomography for intra- and extrahepatic hepatocellular carcinoma.

Matthanja Bieze1, Heinz-Josef Klümpen, Joanne Verheij, Ulrich Beuers, Saffire S K S Phoa, Thomas M van Gulik, Roelof J Bennink.   

Abstract

UNLABELLED: Diagnosis of hepatocellular carcinoma (HCC) primarily involves imaging. The aim of this study was to assess the accuracy of (18) F-fluorocholine ((18) F-FCH) positron emission tomography (PET) for detection of HCC and evaluation of extent of disease. Patients with HCC >1 cm were included between 2009 and July 2011, and follow-up closed in February 2013. Diagnosis was based on American Association for the Study of Liver Diseases criteria, and all patients underwent (18) F-FCH PET/computed tomography (CT) at baseline before treatment, 6 underwent a second PET/CT posttreatment, and 1 a third during follow-up. Whole-body PET and low-dose CT imaging were performed 15 minutes after (18) F-FCH injection. Evaluation of imaging was done with standardized uptake value (SUV) ratios: SUV maximum of the lesion divided by the SUV mean of surrounding tissue. Statistical analyses included descriptive analyses, receiver operating characteristic curve, McNemar's test, and Kaplan-Meier's test at 5% level of significance. Twenty-nine patients revealed 53 intrahepatic lesions. In 48 of 53 lesions, (18) F-FCH PET was positive (SUVratio , 1.95 ± 0.66; sensitivity, 88%; specificity, 100%). PET/CT showed uptake in 18 extrahepatic lesions and no uptake in 3 lesions affirmed non-HCC lesions; all lesions were confirmed with additional investigation (accuracy, 100%). In 17 of 29 patients, additional lesions were found on PET/CT imaging, with implications for treatment in 15 patients. Posttreatment PET/CT showed identical results, compared with standard treatment evaluation.
CONCLUSION: This study shows additional value of (18) F-FCH PET/CT for patients with HCC. (18) F-FCH PET/CT has implications for staging, management, and treatment evaluation because of accurate assessment of extrahepatic disease.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24123111     DOI: 10.1002/hep.26781

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  11 in total

Review 1.  Functional imaging of hepatocellular carcinoma.

Authors:  Tim Ch Hoogenboom; Mark Thursz; Eric O Aboagye; Rohini Sharma
Journal:  Hepat Oncol       Date:  2016-03-29

2.  Baseline and Post-treatment 18F-Fluorocholine PET/CT Predicts Outcomes in Hepatocellular Carcinoma Following Locoregional Therapy.

Authors:  Michael C Wallace; Kenny Sek; Roslyn J Francis; Shaun Samuelson; John Ferguson; Jonathan Tibballs; Ali Asad; David B Preen; Gerry MacQuillan; George Garas; Leon A Adams; Gary P Jeffrey
Journal:  Dig Dis Sci       Date:  2019-08-22       Impact factor: 3.199

3.  Transcatheter arterial chemoembolization as an examination method for hepatocellular carcinoma undetected by B-mode ultrasound, computed tomography and digital subtratcion angiography: A case report.

Authors:  Zongquan Xu; Chen Yu; Shufang Wang; Guohui Xu
Journal:  Oncol Lett       Date:  2015-07-01       Impact factor: 2.967

4.  Diagnostic accuracy of ¹¹C-choline PET/CT in comparison with CT and/or MRI in patients with hepatocellular carcinoma.

Authors:  Egesta Lopci; Guido Torzilli; Dario Poretti; Lauro J Souza de Neto; Matteo Donadon; Lorenza Rimassa; Ezio Lanza; Juliano Guerra Sabongi; Roberto Ceriani; Nicola Personeni; Angela Palmisano; Vittorio Pedicini; Tiziana Comito; Marta Scorsetti; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-05-12       Impact factor: 9.236

5.  Diagnostic role of radiolabelled choline PET or PET/CT in hepatocellular carcinoma: a systematic review and meta-analysis.

Authors:  Francesco Bertagna; Mattia Bertoli; Giovanni Bosio; Giorgio Biasiotto; Ramin Sadeghi; Raffaele Giubbini; Giorgio Treglia
Journal:  Hepatol Int       Date:  2014-09-03       Impact factor: 6.047

6.  Joint analysis of multiple high-dimensional data types using sparse matrix approximations of rank-1 with applications to ovarian and liver cancer.

Authors:  Gordon Okimoto; Ashkan Zeinalzadeh; Tom Wenska; Michael Loomis; James B Nation; Tiphaine Fabre; Maarit Tiirikainen; Brenda Hernandez; Owen Chan; Linda Wong; Sandi Kwee
Journal:  BioData Min       Date:  2016-07-29       Impact factor: 2.522

7.  Construction and Evaluation of the Tumor-Targeting, Cell-Penetrating Multifunctional Molecular Probe iCREKA.

Authors:  Li-Juan Wang; Hong-Sheng Li; Quan-Shi Wang; Hu-Bing Wu; Yan-Jiang Han; Wen-Lan Zhou; Meng Wang; Shun Huang
Journal:  Contrast Media Mol Imaging       Date:  2018-03-04       Impact factor: 3.161

8.  Exosomal MiR-744 Inhibits Proliferation and Sorafenib Chemoresistance in Hepatocellular Carcinoma by Targeting PAX2.

Authors:  Guanghui Wang; Wei Zhao; Huxia Wang; Guanglin Qiu; Zhengdong Jiang; Guangbing Wei; Xuqi Li
Journal:  Med Sci Monit       Date:  2019-09-25

9.  Gastric wall metastases from hepatocellular carcinoma: case report and review of the literature.

Authors:  Moheieldin M Abouzied; Ahmed Fathala; Ahmad AlMuhaideb; Hadeel Almanea; Abdulaziz S Al-Sugair; Rasha AlSkaff; Mohammed H Al-Qahtani
Journal:  Radiol Case Rep       Date:  2020-12-22

10.  Hypoxia-induced modulation of glucose transporter expression impacts 18F-fluorodeoxyglucose PET-CT imaging in hepatocellular carcinoma.

Authors:  Hongping Xia; Jianxiang Chen; Hengjun Gao; Shik Nie Kong; Amudha Deivasigamani; Ming Shi; Tian Xie; Kam M Hui
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-12       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.